Overview

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and this study will evaluate the side effects and effectiveness of this combination.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborators:
Biogen
Genentech, Inc.
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine